Tevard Biosciences was founded by Daniel Fischer and Warren Lammert, parents of girls with Dravet Syndrome and Harvey Lodish, a professor at MIT and Whitehead Institute for Biomedical Research.
Tevard Biosciences is developing gene therapy platforms to target rare diseases such as Dravet syndrome and disorders caused by haploinsufficiency and/or premature stop codons, which traditional gene therapy approaches do not target. Dravet syndrome is also known as Severe Myoclonic Epilepsy of Infancy (SMEI), a condition caused by a mutation in the SCN1A gene required for brain cell function, in 85% of cases.
The company is housed at LabCentral, a shared laboratory space for launching life-sciences and biotech startups. Tevard Biosciences won a Pfizer-sponsored LabCentral “Golden Ticket” in 2018, which provides one year of bench space for one scientist with infrastructure and services.
Member Board Of Directors
Daniel Fischer - Tevard Biosciences | Biotech Showcase Speaker
Documentaries, videos and podcasts
- Gene therapyGene Therapy uses genes to treat or prevent disease. Type of gene therapy include replacing a mutated gene with a healthy copy, inactivating or knocking out a mutated gene or introducing a new gene to fight disease.
- Harvey LodishAmerican biologist
- Dravet syndromeAn epilepsy that is characterized by frequent febrile seizures with onset before 1 year.